ZOLL Strengthens Growth Trajectory for Asahi Kasei's Healthcare Sector with U.S. Launch of the Next-Generation LifeVest® WCD and Rollout of the Most Comfortable LifeVest Garment Ever, Reinforcing Position as Leader in WCD Category
MWN-AI** Summary
Asahi Kasei's healthcare sector, through its subsidiary ZOLL® Medical, has announced the launch of the next-generation LifeVest® wearable cardioverter defibrillator (WCD) in the U.S., further solidifying its leadership position in the WCD market. This launch is complemented by the introduction of the most comfortable LifeVest garment, designed to enhance patient experience and usability. The LifeVest is already renowned—having protected over one million lives and featured in more than 140,000 peer-reviewed clinical publications—making it the most extensively studied device in its category.
Ken Shinomiya, leader of Asahi Kasei's Healthcare sector, emphasizes the significance of these advancements, highlighting that the new LifeVest garment, crafted from lightweight and athleisure-inspired fabrics, accommodates a wide range of patient sizes. Enhanced features, including plush straps and flat-lock stitching, make it preferable for patients, thereby increasing the likelihood of clinical adoption.
ZOLL's commitment to innovation is further demonstrated by the integration of artificial intelligence in its WCDs, reducing false alarms and improving patient safety. The latest iteration continues to incorporate this AI-enhanced algorithm, ensuring reliable protection for patients at risk of sudden cardiac death, especially those with newly diagnosed heart failure.
Asahi Kasei is targeting significant growth in its Critical Care division, aiming for an operating income of ¥55 billion by fiscal 2027. This strategy, supported by high recurring revenues and robust operating margins, positions the Healthcare sector for sustained growth and profitability in the coming years. The combination of advanced technology, extensive clinical data, and a focus on patient comfort bodes well for ZOLL's continued dominance in the WCD market.
MWN-AI** Analysis
Asahi Kasei’s recent advancements in ZOLL Medical’s LifeVest wearable cardioverter defibrillator (WCD) signify a notable strengthening of its healthcare sector, particularly in the U.S. market. With the introduction of the next-generation LifeVest and the rollout of a more comfortable garment, the company is poised to enhance its competitive edge in the WCD category.
The market dynamics favor Asahi Kasei as an increasing number of patients and clinicians recognize the need for heart failure management solutions. The LifeVest has already established itself as a leader, boasting over one million patients protected and numerous clinical studies underscoring its effectiveness, notably the SCD-PROTECT study. These factors not only validate the product's commitment to safety and innovation but also increase the potential for higher adoption rates, particularly among patients at an elevated risk of sudden cardiac events.
Investor sentiment should be optimistic, given ZOLL's strategic focus on critical care. The target operating income of ¥55 billion by fiscal 2027 reflects a strong commitment to ongoing growth and profitability. Moreover, the incorporation of artificial intelligence to minimize false alarms enhances patient safety and reliability, appealing to both clinicians and patients—a crucial influencing factor in market selection.
From a financial perspective, Asahi Kasei’s robust unit growth and high recurring revenue present a compelling case for potential investors. The company’s market position, driven by innovation and clinical success, positions it well for durable revenue growth and operational efficiency in the years ahead.
In conclusion, Asahi Kasei’s proactive approach in enhancing the LifeVest product lineup aligns with evolving healthcare needs. Investors should analyze the potential upside in stocks as the company reinforces its leadership in the WCD market and progresses toward its financial objectives.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Asahi Kasei announced that ZOLL ® Medical, an Asahi Kasei company, has launched the next-generation LifeVest ® wearable cardioverter defibrillator (WCD) in the U.S., and completed the U.S. rollout of the most comfortable LifeVest garment ever.¹ With more than 140,000 patients in peer-reviewed clinical publications and well over one million lives protected, LifeVest is the most used, studied and proven wearable defibrillator.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260108814084/en/
ZOLL LifeVest
ZOLL is a global leader in medical devices and related software and diagnostic tools used in critical care. As part of its growth strategy, Asahi Kasei positions Critical Care as a First Priority business, targeting operating income of ¥55.0 billion in fiscal 2027. The latest advancements to the LifeVest WCD reflect ZOLL’s commitment to continuous innovation, and positions ZOLL to continue leading and sustaining growth in the expanding WCD category.
“With its advanced technology, unmatched safety data, and now an even more comfortable garment, LifeVest set the standard for WCDs for patients at temporarily elevated risk of sudden cardiac death,” said Ken Shinomiya, Leader of the Healthcare sector of Asahi Kasei. “The success of the LifeVest WCD positions ZOLL and Asahi Kasei for even more clinical adoption, continued market expansion, durable revenue growth, and strong profitability in the years ahead.”
ZOLL continues to lead the WCD category, driven by more than two decades of engineering expertise, patient feedback, and clinical evidence. More clinicians and patients are choosing the LifeVest WCD, supported by a growing body of clinical data demonstrating the need for sudden cardiac death protection in newly diagnosed heart failure patients with reduced ejection fraction.² Results from the recent landmark SCD-PROTECT study further reinforce the effectiveness of the LifeVest WCD.?
The next-generation LifeVest garment is preferred by patients for its enhanced comfort and usability.¹ Built on progressive advancements from prior generations, the garment is designed to support patients in their daily lives outside of the hospital. Enhanced features include lightweight, athleisure-inspired performance fabric, soft plush straps, flat-lock stitching, and the largest range of garment sizes available, accommodating chest measurements from 26” to 56”.
ZOLL also pioneered the use of artificial intelligence in WCDs, introducing an AI-enhanced algorithm in 2018 that reduced false alarms to a median of zero at 90 days.³ The latest generation LifeVest continues to incorporate this AI-enhanced algorithm to support reliable patient protection further.
Asahi Kasei’s Healthcare sector continues to experience robust unit growth, high recurring revenue from clinical practice standardization, and strong operating margins. To view Asahi Kasei’s latest financial results, visit https://www.asahi-kasei.com/ir/library/financial_briefing/ .
About ZOLL
ZOLL, an Asahi Kasei company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and cardiac monitoring, circulation enhancement and CPR feedback, supersaturated oxygen therapy, data management, ventilation, therapeutic temperature management, and sleep apnea diagnosis and treatment, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, as well as lay rescuers, improve patient outcomes in critical cardiopulmonary conditions. For more information, visit www.zoll.com .
About Asahi Kasei
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 50,000 employees worldwide, the company contributes to sustainable society by providing solutions to the world’s challenges through its three business sectors of Healthcare, Homes, and Material. For more information, visit www.asahi-kasei.com .
Asahi Kasei is also dedicated to sustainability initiatives and is contributing to reaching a carbon neutral society by 2050. To learn more, visit https://www.asahi-kasei.com/sustainability/ .
Asahi Kasei Corporation (TSE: 3407) is committed to contributing to life and living for people around the world while generating superior long-term returns for shareholders. For more information on Asahi Kasei’s growth strategy and financial objectives, please visit the Investor Relations section at https://www.asahi-kasei.com/ir/ .
1. | Data on file, 20c1184_a01. Garment Comparative Wear Test. |
2. | Based on commercial data as of November 2025. |
3. | Arkles J, Delaughter C, D’Souza B. A novel artificial intelligence based algorithm to reduce wearable cardioverter-defibrillator alarms. J Interv Cardiac Electrophysiol. 2023. https://doi.org/10.1007/s10840-023-01497-w . |
4. | David Duncker, Eloi Marijon, Marco Metra, Olivier Piot, Marat Fudim, Uwe Siebert, Norbert Frey, Lars Siegfried Maier, Johann Bauersachs, Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study, European Heart Journal, 2025;, ehaf668, https://doi.org/10.1093/eurheartj/ehaf668 |
| Disclaimer: A controlled, head-to-head study evaluating the comparative performance of available WCD devices has not been done. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260108814084/en/
North America:
Asahi Kasei America Inc.
Christian OKeefe
christian.okeefe@ak-america.com
Europe:
Asahi Kasei Europe GmbH
Sebastian Schmidt
sebastian.schmidt@asahi-kasei.eu
FAQ**
How does the launch of the next-generation LifeVest by Asahi Kasei Corp AHKSF position the company to achieve its target operating income of ¥55.0 billion in fiscal 2027?
In what ways does the AI-enhanced algorithm incorporated in the LifeVest contribute to ZOLL's leadership in the wearable cardioverter defibrillator market for Asahi Kasei Corp AHKSF?
What specific clinical outcomes have emerged from the recent SCD-PROTECT study that reinforce the LifeVest's effectiveness for Asahi Kasei Corp AHKSF?
How does Asahi Kasei Corp AHKSF plan to leverage its advancements in the LifeVest WCD for continued market expansion and durable revenue growth in the healthcare sector?
**MWN-AI FAQ is based on asking OpenAI questions about Asahi Kasei Corp ADR (OTC: AHKSY).
NASDAQ: AHKSY
AHKSY Trading
-0.65% G/L:
$19 Last:
44,247 Volume:
$18.97 Open:
